What is Neurocentria?
Neurocentria Inc. is a biopharmaceutical company dedicated to pioneering novel therapeutic solutions for individuals grappling with neuropsychiatric and neurodegenerative disorders. The company's core innovation lies in a proprietary compound designed to bolster synaptic function and stimulate synaptogenesis by modulating intracellular magnesium levels. Neurocentria's robust pipeline includes clinical programs targeting ADHD, depression, and Alzheimer's disease, complemented by a nutraceutical offering aimed at enhancing cognitive health in the general population. Their patient-centric and scientifically rigorous methodology positions them to deliver transformative treatment options.
How much funding has Neurocentria raised?
Neurocentria has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Neurocentria
PPP
Public-Private Partnership
What's next for Neurocentria?
With its substantial late-stage funding, Neurocentria is strategically positioned to accelerate its clinical development programs and advance its innovative therapies through regulatory pathways. The recent strategic investment signals strong confidence from stakeholders in the company's potential to address significant unmet needs in neurological and psychiatric care. Future endeavors will likely focus on expanding clinical trial reach, scaling manufacturing capabilities, and potentially forging strategic partnerships to broaden market access for their groundbreaking treatments.
See full Neurocentria company page
